WOCKHARDT LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 575.3 INR | +0.27% |
|
-1.30% | +35.57% |
| 03/04 | Wockhardt Limited Announces Cessation of Independent Directors | CI |
| 14/02 | Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
| Sales 2022 | 32.3B 387M | Sales 2023 | 26.51B 318M | Capitalization | 22.18B 266M |
|---|---|---|---|---|---|
| Net income 2022 | -2.44B -29.25M | Net income 2023 | -5.59B -67.02M | EV / Sales 2022 | 1.74 x |
| Net Debt 2022 | 18.16B 218M | Net Debt 2023 | 20.68B 248M | EV / Sales 2023 | 1.62 x |
| P/E ratio 2022 |
-13
x | P/E ratio 2023 |
-3.97
x | Employees | 2,740 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 46.31% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.27% | ||
| 1 week | -1.30% | ||
| Current month | -1.78% | ||
| 1 month | -1.78% | ||
| 3 months | +26.73% | ||
| 6 months | +157.23% | ||
| Current year | +35.57% |
1 week
560.50
595.00
1 month
535.00613.00
Current year
402.65630.00
1 year
167.00630.00
3 years
145.15804.90
5 years
145.15804.90
10 years
145.152 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 51 | 01/09/01 | |
| Founder | 81 | 01/67/01 | |
Deepak Madnani
DFI | Director of Finance/CFO | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 81 | 01/67/01 | |
| Director/Board Member | 71 | 29/20/29 | |
| Chief Executive Officer | 51 | 01/09/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 117 M€ | +1.62% | - | |
| 0.00% | 34 M€ | +2.43% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 575.3 | +0.27% | 197 274 |
| 26/24/26 | 573.8 | +0.54% | 440,684 |
| 25/24/25 | 570.6 | +0.43% | 106,353 |
| 24/24/24 | 568.2 | -0.11% | 118,797 |
| 23/24/23 | 568.8 | -0.65% | 326,914 |
Delayed Quote NSE India S.E., April 29, 2024 at 05:10 pm IST
More quotes
Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Companyâs products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
Sector
Pharmaceuticals
Calendar
24/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +35.57% | 1.06B | |
| +20.81% | 43.34B | |
| +20.44% | 21.96B | |
| +13.30% | 14.09B | |
| +12.97% | 13.64B | |
| +39.74% | 11.43B | |
| -8.59% | 6.86B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +8.46% | 5.22B |
- Stock Market
- Equities
- WOCKPHARMA Stock
